Bigger Is Not Always Better: Tumor Size and Prognosis in Advanced Melanoma

Tumor burden is a key consideration for the treatment of solid malignancies. Large baseline tumor size (an assessment of volume of disease in target lesions prior to treatment), elevated lactate dehydrogenase (LDH), and site of disease are prognostic of poor overall survival (OS) for patients with a...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 24; no. 20; pp. 4915 - 4917
Main Authors Warner, Allison Betof, Postow, Michael A.
Format Journal Article
LanguageEnglish
Published United States 15.10.2018
Online AccessGet full text

Cover

More Information
Summary:Tumor burden is a key consideration for the treatment of solid malignancies. Large baseline tumor size (an assessment of volume of disease in target lesions prior to treatment), elevated lactate dehydrogenase (LDH), and site of disease are prognostic of poor overall survival (OS) for patients with advanced melanoma treated with pembrolizumab. Clin Cancer Res; 24(20); 4915–7. ©2018 AACR. See related article by Joseph et al., p. 4960
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Commentary-3
content type line 23
ISSN:1078-0432
1557-3265
1557-3265
DOI:10.1158/1078-0432.CCR-18-1311